Structured evidence table for Berberine Lipid Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Berberine Lipid Randomized Trial | Diabetes mellitus and prediabetes represent major global health challenges associated with metabolic and cardiovascular complications. | 1 | Nampalliwar A (2026) | A Systematic Review of Herbal Medicines in the Management of Diabetes: Efficacy, Toxicological Profiles, and Clinical Safety Considerations. |
| Berberine Lipid Randomized Trial | This review was conducted to evaluate herbal medicines as complementary strategies for glycaemic control and metabolic risk reduction. | 1 | Nampalliwar A (2026) | A Systematic Review of Herbal Medicines in the Management of Diabetes: Efficacy, Toxicological Profiles, and Clinical Safety Considerations. |
| Berberine Lipid Randomized Trial | Berberine lowers both lipids and glucose, yet its role on cardiometabolic disease risk remain unclear. | 2 | Zhao JV (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization. |
| Berberine Lipid Randomized Trial | Based on a randomized controlled trial of berberine (registered in ClinicalTrials.gov on Dec 2018, NCT03770325), leveraging proteomics and sex hormones data, we built a signature reflecting response to berberine using elastic net regression. | 2 | Zhao JV (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization. |
Source documents